Viking Therapeutics announced plans to raise $200 million through common stock and $200 million via convertible senior notes due 2032, with options for additional sales. The funds will support clinical development and commercialization of its obesity and metabolic disease drug programs, including VK2735 and VK3019. The offerings are independent of each other and managed by Morgan Stanley and J.P. Morgan. Proceeds will advance Viking's pipeline and general corporate purposes.
Viking Therapeutics announced plans to raise $400 million through common stock and convertible senior notes. For readers following the health sector, here is Pluang's market snapshot as of Sep 24, 2026 03:02 WIB: out of 100 priced US health stocks, 37 rose and 63 fell today. Notable movers include DNA (Ginkgo Bioworks Holdings Inc) down 8.54% at USD 8.57 with 70% sell order activity, BNGO (BioNano Genomics Inc) up 7.51% at USD 1.86 with 93% sell order activity, and SANA (Sana Biotechnology Inc) down 7.21% at USD 3.09 with 93% buy order activity.
BlackBerry is expected to report Q3 earnings with an EPS of $0.04 and revenue around $143.55 million, in line with company guidance. The company has a strong track record of beating earnings estimates, driven by growth in its QNX automotive software ...
Wheeler REIT (WHLR) surged 190.91% after a 1-for-9 reverse stock split, though no new catalyst was confirmed. Artelo Biosciences (ARTL) rose 74% following a provisional patent application for its obesity drug candidate ART27.13, based on early mouse ...
Costco Wholesale announced $93.9 billion in net sales for its fiscal Q4, up 11.3% from last year, with comparable sales rising 9.4%. The full earnings report on September 24 will reveal membership fees, total revenue, expenses, and profit details. An...
Jefferies reaffirmed its Buy rating on Life Time Group Holdings (LTH), citing a positive earnings outlook supported by a Zacks Rank of #2. The stock trades around $38.85 with a market cap near $8.68 billion. Despite this optimism, Executive Vice Pres...
Kuehn Law is investigating Fractyl Health for allegedly misleading shareholders about the effectiveness of its outpatient therapy, Revita. The lawsuit claims the company overstated Revita's clinical and commercial prospects and failed to disclose ope...
